Human Health · Animal Health · Environmental Health

The Translational Science
& Evidence Solution.
One Health, One Solution — Human, Animal & Environmental Health.

HH Global Holdings is a translational science and evidence platform. We combine genomics, diagnostics, bioinformatics, regulatory intelligence and evidence systems to take scientific work from biomarker discovery through to compliant submission. Our integrated capability, preclinical research, ISO 17025/15189 compliance, multiplex diagnostic development, and regulatory evidence generation, translates seamlessly across human, animal and environmental health. One partner, one unified scientific framework, no handoff gaps.

One Health Framework How We Work
HH Global research team at work
PCR workstation
Researcher at biosafety hood
Presenting research outcomes
AstraZeneca Trial Delivery Regulatory by Design Government Advisory NHS Clinical Access
Who We Serve

Do You Recognise
Yourself Here?

Our clients come to us at the moment their science needs to become real, validated, compliant, and capable of withstanding regulatory or legal scrutiny. If one of these situations sounds familiar, we should talk.

01
Embedded Scientific Capability

Early-Stage Companies

You have the science but not the credentialled team to validate or advance it. You need real scientists, not a consultancy. Whether it is systematic reviews, technical advisory, or R&D without the overhead of an in-house lab, we become your scientific function.

SMEs · Biotech startups · Environmental consultancies · Independent researchers

Scientific Practice →
02
Lab Build & Accreditation

Organisations Building or Upgrading Labs

We design laboratories around what the client needs to achieve, regulatory compliance is structural, not an afterthought. Labs built to ISO 17025/15189 from the ground up, not retrofitted after the fact. From equipment specification and Standard Operating Procedure (SOP) development to UK Accreditation Service (UKAS) audit preparation, we have built accredited labs from empty rooms, designed for compliance from day one.

NHS Trusts · Universities · Overseas health ministries · Private laboratories

Explore LabArchitect™ →
03
Diagnostic Development

Pharma, Biotech & Agri-Health Companies

You have a diagnostic concept, an assay, a lateral flow test, a genomic panel, or an environmental sensor, and you need validation, clinical or field evidence, and a regulatory pathway to certification for the UK and European markets (UKCA and CE marks) or beyond. From women's health and menopause biomarkers to camelid genomics and population-scale research programmes, we take diagnostics from concept to compliant submission across human, animal, and environmental applications.

Pharmaceutical companies · Biotech startups · Drug discovery companies · Women's health companies · Population health programmes · Agricultural diagnostics · Veterinary health companies

Diagnostic & Evidence Sciences →
04
UK Market Entry Support

International Organisations & Investors

You are entering a new market, the UK, UAE, Europe, or beyond, and you need local scientific credibility, regulatory alignment, and laboratory capability to make it work. Whether you are a government agency, family office, or investment vehicle establishing diagnostic infrastructure, or an international programme requiring species-specific genomics capability, equine, camelid, or otherwise, we provide the scientific and operational infrastructure your expansion requires.

Government health agencies · International distributors · Family offices · Overseas health ministries · UAE & Gulf region genomics programmes

Get in Touch →
How We Compare

Niche Specialist with Infrastructure.

Buyers of regulated science typically face a binary: an industrial CRO with scale but limited customisation, or a solo academic with depth but no operating infrastructure. Our practice is built to occupy the gap between them.

Industrial CRO

Scale & capacity

  • High throughput
  • Standardised workflows
  • Limited customisation
  • Programme-level engagement
  • Generalist account team

HH Global Holdings

Specialist depth with infrastructure

  • Custom assay & method design
  • ISO 17025 / 15189 operating model
  • Peer-reviewed scientific lead
  • End-to-end accountability
  • Practice continuity across engagements

Solo Scientist

Depth without delivery

  • Deep specialist knowledge
  • Personal credibility
  • No accredited infrastructure
  • Project-by-project, no continuity
  • Limited bandwidth
Why HH Global Holdings — Operational Entities

Fundamental Science.
Commercial Insight.

Fragmented CRO (Contract Research Organisation) partnerships are where science goes to slow down. Handoff gaps, misaligned regulatory assumptions, and broad-spectrum guesswork all compound into costly delays. Here is how we eliminate them.

01

The Full Pipeline

Most CROs can take you part of the way. The gap between where one ends and the next begins is where programmes stall. We cover the entire development pathway, from biomarker identification and preclinical work through to ISO 17025/15189 compliance. One partner, no handoff gaps, no restarts.

02

Targeted, Not Spray-and-Hope

In vitro to in vivo translation is difficult, costly, and often fails when it relies on broad-spectrum assumptions. We identify the lock, find the key model, and replicate the mechanism, targeted development from day one. That is why our clients reach submission faster, with fewer failed iterations.

03

Regulatory-First by Design

Navigating regulatory requirements is one of the most stressful stages of development, and the most expensive to get wrong. We build every programme to meet compliance from day one, not as an afterthought. The result: evidence packages that work first time, submissions without surprises, and no expensive rework.

One Health Framework

Three Domains.
One Pipeline.

Human, animal, and environmental health are interconnected. So is our capability. We cover the complete development pathway across all three domains, with the same rigour, the same regulatory discipline, and the same 100% client retention.

01 · Human Health

Drug Development to Diagnostics

Too often, promising human health science stalls at the boundary of a CRO's capability, handed off, restarted, or simply abandoned. We cover the complete human health development pathway, from preclinical research through Phase 1 delivery, and from bench-top assays to point-of-care devices deployable in the field.

  • →Full-pipeline CRO: preclinical to Phase 1
  • →Multiplex lateral flow (patent pending), 20–60 analytes, 3 drops of blood
  • →Women's health & menopause biomarker diagnostics
  • →Population health research & large-scale biomarker programmes
  • →Systematic reviews & evidence synthesis
  • →Specials licences & unlicensed drug access
02 · Animal Health

Veterinary Diagnostics & Therapeutics

Animal health diagnostics have lagged behind human medicine for decades, not because the science is harder, but because the commercial incentive was smaller. That gap is closing. We apply the same diagnostic rigour across species, because pathogens don't respect species boundaries, and neither do we.

  • →Lateral flow testing for animal disease, TB, brucellosis, any pathogen
  • →Genomic profiling, equine, camelid, and high-value species
  • →Vaccine development & fractionation across species
  • →Veterinary specials licences & cross-species regulatory alignment
  • →Medicinal cannabis, veterinary & human pathways
  • →Any species, companion, livestock, camelid, wildlife
03 · Environmental Health

From Soil to Air to Legal Standard

Environmental health decisions, in agriculture, biosecurity, and public safety, are too often made without rigorous scientific evidence. We provide the science that holds up in labs and in front of regulators.

  • →Plant & crop pathogen diagnostics
  • →Agri-environmental genomic analysis
  • →Bio-defence & CBRN (Chemical, Biological, Radiological, Nuclear) pathogen detection
How We Engage

A Structured Pathway
from Enquiry to Impact

Every engagement follows a structured, gated process, ensuring scientific rigour at every stage and clear decision points before progressing to the next phase.

1

Discovery

Initial scoping, needs assessment, feasibility, and programme definition with your team.

2

Preclinical & Research

Literature review, systematic evaluation, laboratory work, biomarker identification, and early-stage development.

3

Validation

Testing, optimisation, statistical analysis, reproducibility, and peer-reviewed evidence generation.

4

Regulatory

ISO 17025/15189 compliance, MHRA and CE/UKCA regulatory submissions, compliance documentation, and expert evidence packages.

5

Deployment

Commercialisation, manufacturing partnerships, scaling, ongoing support, and real-world monitoring across target markets.

Start a Conversation

Let's Explore How
We Can Work Together

Whether you need diagnostic platform development, expert evidence services, preclinical drug development, or a full laboratory setup, we'd welcome the opportunity to discuss your requirements.

Address

73 Cornhill, London
EC3V 3QQ